Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs provides an AI-Integrated Preclinical & Translational Service to address critical challenges in immunotherapy development, including high clinical attrition rates, unpredictable high-grade cytokine release syndrome (CRS), and the lack of robust biomarkers for demonstrating patient response in solid tumors. This service enables improved trial success and streamlined regulatory submission through proprietary predictive modeling and comprehensive multi-omics data integration. By transforming complex real-world and experimental data into actionable insights, Creative Biolabs supports the development of safer and more effective CAR-T and TCR-T therapies with enhanced clinical confidence.
AI-driven translational research is transforming CAR/TCR development by enabling precise prediction of therapeutic response and toxicity. Recent studies demonstrate that machine learning models integrating multi-omics, clinical parameters, and imaging data can identify key biomarkers and improve patient stratification. Additionally, real-world evidence analytics enhances long-term efficacy and safety evaluation. Together, these approaches establish a data-driven framework that accelerates clinical translation and improves therapeutic outcomes.
Fig.1 Machine learning model for predicting responses to CAR-T cell therapy. 1
At Creative Biolabs, we bridge the translational gap by utilizing advanced machine learning algorithms to analyze patient response patterns and safety signals. We provide the high-level analytical rigor needed to move your candidate from the bench to the bedside with confidence.
Our service supports patient response prediction by developing predictive models that combine clinical, genomic, and immune profiling data to distinguish responders from non-responders. It also facilitates biomarker discovery through multi-omics analysis and AI-assisted feature selection to identify reliable molecular, cellular, and functional markers. In addition, we integrate real-world evidence by deriving practical insights from clinical documentation and longitudinal data to verify therapeutic performance and optimize translational strategies by aligning preclinical models with clinical endpoints to enhance clinical trial success.
Discover How We Can Help - Request a Consultation.
| Multi-Modal Data Integration | AI-Based Predictive Modeling |
|
|
| Biomarker Discovery Platforms | Real-World Evidence Analytics |
|
|
Required Starting Materials: To initiate the service, clients typically provide raw data from Phase I/II trials, longitudinal patient clinical records, or specific CAR-T construct sequences and in vitro expansion kinetics.
Final Deliverables: You will receive a Translational Insight Report, a Predictive Risk-Assessment Algorithm tailored to your lead candidate, and a Regulatory-Ready Biomarker Validation Data Set.
Creative Biolabs leverages AI to identify predictive biomarkers from multi-omics data, enabling patient stratification, response prediction, and improved clinical success for CAR/TCR therapies.
Learn More →Creative Biolabs offer AI-Powered Single-Cell Multi-Omics Analysis Service, revealing cellular heterogeneity, immune dynamics, and functional states to guide CAR/TCR design and translational insights.
Learn More →Creative Biolabs integrates AI with spatial transcriptomics to map tumor architecture and immune landscapes, supporting targeted CAR-T strategies and improved understanding of tumor microenvironments.
Learn More →Creative Biolabs uses AI to analyze longitudinal patient data, enabling dynamic monitoring of treatment response, resistance mechanisms, and disease progression during CAR/TCR therapy.
Learn More →Creative Biolabs develops AI-guided solutions for universal CAR-T therapies, optimizing gene editing, immune compatibility, and persistence to enable scalable, off-the-shelf cell therapy development.
Learn More →Q: How does AI improve upon standard CRS monitoring?
A: Traditional monitoring is reactive (treating symptoms after they appear). Our AI models analyze subtle changes in vitals and coagulation markers to predict high-grade events up to 48 hours before clinical onset.
Q: Can your models handle data from solid tumor trials?
A: Yes. We specialize in identifying the unique infiltration signatures and TME immunosuppression markers specific to solid malignancies.
Q: Is my trial data secure?
A: We operate under strict confidentiality agreements and use encrypted, siloed environments for all AI model training.
Q: Do we need to use your specific assays for the AI to work?
A: While we offer compatible assays, our AI is platform-agnostic and can ingest data from most standard clinical and omic platforms.
Creative Biolabs serves as your committed partner throughout the intricate journey of CAR-T and TCR-T therapy development. Covering everything from early preclinical modeling to advanced translational research, our AI-integrated solutions deliver precise, data-driven insights to streamline development workflows. By combining deep technical expertise with intelligent tools, we help accelerate the launch of life-saving immunotherapies. Contact our team today to learn more and discuss your unique project needs.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
